Instruction for use: Terazosin

Trade name of the drug – Setegis, Kornam, terazosin, Terazosin-Teva, Hytrin, Terazosin hydrochloride dihydrate

The Latin name of the substance Terazosin

Terazosin (genus. Terazosin)

Chemical rational name: 1- (4-Amino-6,7-dimethoxy-2-quinazolinyl) -4 - [(tetrahydro-2-furanyl) carbonyl] piperazine (as hydrochloride)

Gross formula C19H25N5O4

Pharmacotherapeutic group: Alpha-blockers

Drugs affecting the metabolism of the prostate gland and correctors urodynamics

The nosological classification (ICD-10)

I10 Essential (primary) hypertension: hypertension; Arterial hypertension; Arterial hypertension crisis course; Essential Hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Essential hypertension; Primary hypertension; Arterial hypertension, complications of diabetes; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; arterial Hypertension; malignant Hypertension; Hypertonic disease; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; Isolated systolic hypertension

I15 Secondary hypertension: Arterial hypertension, complications of diabetes; hypertension; The sudden increase in blood pressure; Hypertensive disorders of blood circulation; hypertensive condition; hypertensive crises; hypertension; arterial Hypertension; malignant Hypertension; hypertensive crises; accelerated hypertension; malignant hypertension; The aggravation of hypertensive disease; Transient hypertension; hypertension; Arterial hypertension; Arterial hypertension crisis course; renovascular hypertension; Hypertension symptomatic; Renal hypertension; Renovascular hypertension; renovascular hypertension; Symptomatic hypertension

N40 Hyperplasia of prostate gland: Prostate adenoma; BPH; Prostatauxe; prostate Hypertrophy; Dysuric disorders caused by benign prostatic hyperplasia; Dizuricheskie disorder with benign prostatic hyperplasia; Dysuria with prostate cancer; Benign prostatic giperpalaziya; Benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2; Benign prostatic hyperplasia I degree; Benign prostatic hyperplasia II degree; Benign prostatic hypertrophy; The disease of the prostate gland; Acute urinary retention related to benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2 in combination with prostatitis; paradoxical ischuria

CAS code 63590-64-7

Description of Terazosin

The white crystalline powder, odorless, soluble in water.

Pharmacological Properties of Terazosin

Pharmachologic effect - Mode of action - hypolipidemic, vasodilating, antidizuricescoe.

Selectively blocking alpha1-adrenergic receptors of the smooth muscles of the splanchnic vessels, prostate and bladder neck. Extends large resistive vessels and reduce peripheral vascular resistance (hypotension), activates the renin-angiotensin-aldosterone system. It relaxes the smooth muscles of the bladder neck and prostate contractile elements reduces dizuricheskih phenomena at its adenoma. It normalizes the plasma lipid profile (reduced content of total cholesterol, triglycerides, VLDL and LDL cholesterol, increases HDL). With prolonged use causes regression of left ventricular hypertrophy.

Once inside quickly and completely absorbed (bioavailability greater than 90%); first-pass biotransformation as negligible, Cmax is reached within 1 hour. At 90-94% plasma protein bound. The four forms of liver metabolite. T1 / 2 - 12 hours 40% is excreted by the kidney (10% unchanged) and 60% -. Intestine (more than half in the form of biodegradation products). When liver disease is reduced clearance, and the effects are prolonged.

The hypotensive effect is 15 minutes after receiving a single dose, after 2-3 hours, reaches a maximum, lasts up to 24 hours In benign prostatic hyperplasia develops clinical improvement after 2 weeks of continuous use, and durable therapeutic effect -. For 4-6 weeks.

The efficiency of terazosin in the treatment of heart failure in the initial stage and hyperlipidemia.

Indications for Terazosin

Symptomatic treatment of benign prostatic hyperplasia, hypertension (as monotherapy or in combination therapy).

Contraindications for Terazosin

Hypersensitivity, hypotension, pregnancy, lactation, children's age.

Restrictions to application

Coronary artery disease and other heart disease, kidney and / or liver failure, cerebrovascular accident, hypertensive retinopathy grade III or IV, diabetes mellitus type 1.

Pregnancy and breast-feeding

When pregnancy is possible, if the benefit to the mother outweighs the potential risk to the fetus.

Category effects on the fetus by FDA - C.

At the time of treatment should stop breastfeeding.

Side effect of Terazosin

Weakness, fatigue, drowsiness, restlessness, headache, dizziness, paresthesia, decreased libido, impaired vision, ringing in the ears, "the phenomenon of the first dose" (a sharp drop in blood pressure, up to orthostatic collapse after the first dose, usually in combination therapy with diuretics or beta-blockers), hypotension, tachycardia, arrhythmias, peripheral edema, cough, bronchitis, dry mouth, sore throat, nausea, vomiting, arthralgia, myalgia, decline in hematocrit and hemoglobin, leukopenia, hypoalbuminemia, hypoproteinemia, flu-like syndrome, allergic reactions.

Overdose of Terazosin

Symptoms: tachycardia, hypotension, orthostatic collapse.

Treatment: the patient in a horizontal position, the bed lowered head end, in / in a liquid, hypertensive drugs. Hemodialysis is ineffective. No specific antidote.

Interaction

It enhances the hypotensive activity of diuretics, blockers, calcium antagonists, myotropic and drugs which depress the renin-angiotensin-aldosterone system.

Antacids reduce the absorption and adsorbents. Adrenomimetiki weaken efficiency.

Routes of administration

Inside.

Precautions for substance Terazosin

After the first dose or during the initial period of treatment may be a "phenomenon of the first dose." To prevent orthostatic collapse initial dose should not exceed 1 mg and assign it should be before bedtime (lying down). Reducing the volume of fluid in the body and bounded salt intake increases the risk of occurrence of postural hypotension. It must be remembered that such phenomena may occur when resuming treatment after a break for a few days. In such cases, the treatment should renew a dose of 1 mg.

Fainting appear in 1% of cases. To develop syncope can cause a rapid increase in the dosage after an "effect of the first dose," as well as the appointment of doxazosin in combination with diuretics and / or other antihypertensive agents.

Before the treatment of BPH is necessary to rule out the presence of malignancy. Patients with BPH blood pressure should be monitored at the beginning of treatment and change of dose during treatment. The efficacy of doxazosin in BPH should be assessed after 4-6 weeks of treatment with maintenance doses.

At the beginning of treatment and at higher doses of the drug to patients is not recommended to engage in potentially hazardous activities that require increased attention and quickness of psychomotor reactions (including driving vehicles). Later, in the course of treatment, these restrictions are set individually.